Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 4Unknown 3Withdrawn 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

NET 3Endocrine 3CNS 2

Conditions

Neuroendocrine Tumors 3Thymus Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplasms 1Meningioma 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
170 enrolled
EndocrineNET

Thymus Neoplasms, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Lund University Hospital

Phase 3 Recruiting
300 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04997317 2025-04-13

PROMENADE

University Hospital, Basel, Switzerland

Phase 1/2 Recruiting
18 enrolled
CNS

Meningioma, Neoplasms

NCT06045260 2024-08-13

LUFOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
100 enrolled
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡